On February 7, 2022 Kyowa Hakko Kirin reported that Consolidated Financial Summary (IFRS)Fiscal 2021 (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607779])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
1. Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (from January 1, 2021 to December 31, 2021)
(1) Consolidated operating results
(2) Consolidated financial position
(3) Consolidated cash flows
2. Dividends
3. Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2022 (from January 1, 2022 to December 31, 2022) Non-Consolidated Results for the Fiscal Year Ended December 31, 2021 (Japanese GAAP) (from January 1, 2021 to December 31, 2021)
(1) Non-consolidated operating results
(2) Non-consolidated financial position
These financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.
* Notice regarding the appropriate use of the earnings forecasts and other special comments
The forward-looking statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
For more information regarding our suppositions that form the assumptions for the earnings forecasts, please see pages 17 and 18 of the attachment, "(5) Outlook for Fiscal 2022" in "
1. Summary of Business Performance and Financial Position."